The Board of pancreatic cancer treatment device company OncoSil Medical Limited announced the appointment of Ms Shelley Steyn as Chief Financial Officer ("CFO") with effect from 5 May 2025. Ms Steyn brings to OncoSil extensive experience with more than 17 years in senior accounting, commercial and financial analysis and audit roles. Ms Steyn joins from Flynn Global ANZ, a division of Flynn Group LP, a multibillion-dollar franchise operator in the United States.
Prior roles include with (then) ASX 200 radiopharmaceutical medical device company, Sirtex Medical; Deloitte Touche Tohmatsu and Grant Thornton. Ms Steyn holds a Bachelor of Commerce and Postgraduate Diploma (Accounting) and is a Chartered Accountant (CA) charter holder. This appointment follows the resignation of Mr. Christian Dal Cin as CFO and Company Secretary, effective 31 March 2025.
